Understand European GMPs and the Role of the QP

7 - 8 June 2011, Washington D.C. Metro Area, USA.
With optional Post-Conference Sessions on June 9, 2011.
Over the past few years the role and duties of the Qualified Person keep increasing in significance and scope. Being the key person in the quality function of a pharmaceutical company, the QP has to consider many issues to fulfil the responsibilities and to comply with the European legislation.

This Conference is designed by QPs and international Experts as a forum with focus on sharing information and experience and on discussing the critical areas of European GMPs and the QP's daily work.

The Conference has been designed for non-European QA and QCU personnel, upper management functions and authority representatives who want to be informed about the latest development regarding European GMPs and the duties and responsibilities of Qualified Persons.

Speakers:

  • Richard M. Bonner, Qualified Person, Formerly with Eli Lilly and Company Ltd., UK
  • Dr Christopher Burgess, Qualified Person, Burgess Analytical Consultancy, UK
  • Dr Dimitrios Catsoulacos, European Medicines Agency, EMA
  • Dr Bernd Renger, Qualified Person, Chairman, European QP Association
  • Dr Janice Soreth, FDA, Office of International Programs at EMA
  • Martine Tratsaert, Qualified Person, Johnson & Johnson, Belgium
  • Mark Tucker, Ph.D., Genentech Inc./Roche Group, USA

Highlights
Understand European GMPs

  • ƒ The European Pharmaceutical Legislation
  • ƒƒ Import/ Export, CEPs and GMP Certificates
  • ƒƒ EU Product Quality Review Requirements versus US Annual Report Requirements

Understand the Role of the QP

    ƒƒ
  • The Legal and Professional Duties of the Qualified Person
  • ƒ EU Inspections in the U.S. and the Involvement of the QP
  • ƒƒ The EU Discretion Paper and the Release of Batches by the QP
  • ƒƒ The Role of the QP in Contract Manufacturing
  • ƒƒ The role of the QP in the Supply Chain and Supplier Qualification
  • ƒƒ The US Quality Unit versus the EU QP

The view of FDA and EMA
With optional Post-Conference Sessions on June 9, 2011

  • ƒƒ Session 1: Case studies: Certification by a QP and Batch Release
  • ƒƒ Session 2: Clinical Trial Supplies: IMP Handling in Europe and the Role of the QP

For further information and registration, please visit:
http://www.gmp-compliance.org/qpag_forum_5.html

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...